Back to top
more

Definitive Healthcare (DH)

(Delayed Data from NSDQ)

$5.62 USD

5.62
196,332

-0.03 (-0.53%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.61 -0.01 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DH or PRVA: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DH vs. PRVA: Which Stock Is the Better Value Option?

Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Definitive Healthcare (DH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Nalak Das headshot

5 Medical Info Systems Stocks to Buy for Stable Returns

by Nalak Das

We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates

by Zacks Equity Research

Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.

Indrajit Bandyopadhyay headshot

3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates

by Indrajit Bandyopadhyay

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Definitive Healthcare Corp. (DH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Definitive Healthcare Corp. (DH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.

Computer Programs and Systems (CPSI) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -33.33% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -13.79% and 0.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Augmedix, Inc. (AUGX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Augmedix, Inc. (AUGX) delivered earnings and revenue surprises of 7.69% and 3.55%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix

by Zacks Equity Research

Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Consider From a Prospering Industry

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.

Definitive Healthcare Corp. (DH) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -4.35% and 6.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Tabula Rasa Healthcare (TRHC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Definitive Healthcare Corp. (DH) Reports Next Week: What You Should Expect

by Zacks Equity Research

Definitive Healthcare Corp. (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva

by Zacks Equity Research

AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.

Lavina Shahu headshot

4 Toxic Stocks That Are Detrimental to Your Portfolio's Health

by Lavina Shahu

Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.

Zacks.com featured highlights CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee

by Zacks Equity Research

CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee have been highlighted in this Screen of The Week article.

Rimmi Singhi headshot

4 Toxic Stocks That You Should Eliminate From Your Portfolio

by Rimmi Singhi

Similar to identifying stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to avoid losses. CSGP, DH, MNTK and WEST are few toxic stocks you should dump now.